Tyra Biosciences (NASDAQ:TYRA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Tyra Biosciences (NASDAQ:TYRA) released its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05, Zacks reports.

Tyra Biosciences Stock Up 1.1 %

Shares of NASDAQ TYRA opened at $9.77 on Friday. Tyra Biosciences has a twelve month low of $9.49 and a twelve month high of $29.60. The firm has a market cap of $494.39 million, a PE ratio of -6.07 and a beta of 1.09. The business has a fifty day simple moving average of $12.46 and a two-hundred day simple moving average of $16.36.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TYRA. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Buy” and an average target price of $30.83.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now directly owns 443,885 shares of the company’s stock, valued at $6,107,857.60. This represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is currently owned by corporate insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.